Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epcoritamab combination study in non-Hodgkin lymphoma
2023-505347-38-00Phase 2Authorised
- Sponsor
- AbbVie Inc.
- Start
- Jun 2022
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 15
01
Overview
Phase 2, open-label trial of epcoritamab in mature B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and 1 more (7 arms), sponsored by AbbVie Inc. Primary endpoint: Dose-limiting toxicities. Planned start Jun 2022; status: authorised.
02
Drugs
epcoritamab
03
Conditions
mature B-cell lymphomadiffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2023-505347-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505347-38-00.